Trial · NCT00729469
Adverse events52
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 52
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Urinary Tract Infection | Infections and infestations | Subjects on Placebo | 23 | 456 | |
| other | Urinary Tract Infection | Infections and infestations | Subjects on Ospemifene 60 mg/Day | 37 | 463 | |
| other | Nasopharyngitis | Infections and infestations | Subjects on Placebo | 16 | 456 | |
| other | Nasopharyngitis | Infections and infestations | Subjects on Ospemifene 60 mg/Day | 20 | 463 | |
| other | Vulvovaginal Candidiasis | Infections and infestations | Subjects on Placebo | 2 | 456 | |
| other | Vulvovaginal Candidiasis | Infections and infestations | Subjects on Ospemifene 60 mg/Day | 18 | 463 | |
| other | Vulvovaginal Mycotic Infection | Infections and infestations | Subjects on Placebo | 2 | 456 | |
| other | Vulvovaginal Mycotic Infection | Infections and infestations | Subjects on Ospemifene 60 mg/Day | 17 | 463 | |
| other | Upper Respiratory Tract Infection | Infections and infestations | Subjects on Placebo | 21 | 456 | |
| other | Upper Respiratory Tract Infection | Infections and infestations | Subjects on Ospemifene 60 mg/Day | 15 | 463 | |
| other | Sinusitis | Infections and infestations | Subjects on Placebo | 25 | 456 | |
| other | Sinusitis | Infections and infestations | Subjects on Ospemifene 60 mg/Day | 11 | 463 | |
| other | Headache | Nervous system disorders | Subjects on Placebo | 21 | 456 | |
| other | Headache | Nervous system disorders | Subjects on Ospemifene 60 mg/Day | 16 | 463 | |
| other | Vaginal Discharge | Reproductive system and breast disorders | Subjects on Placebo | 3 | 456 | |
| other | Vaginal Discharge | Reproductive system and breast disorders | Subjects on Ospemifene 60 mg/Day | 21 | 463 | |
| other | Hot Flush | Vascular disorders | Subjects on Placebo | 15 | 456 | |
| other | Hot Flush | Vascular disorders | Subjects on Ospemifene 60 mg/Day | 32 | 463 | |
| serious | Palpitations | Cardiac disorders | Subjects on Placebo | 1 | 456 | |
| serious | Palpitations | Cardiac disorders | Subjects on Ospemifene 60 mg/Day | 0 | 463 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00729469/events